Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Get Rating) have been assigned a consensus recommendation of “Buy” from the seven analysts that are currently covering the firm, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $8.67.

Several research analysts have weighed in on FUSN shares. B. Riley restated a “buy” rating and issued a $10.00 price target on shares of Fusion Pharmaceuticals in a research note on Thursday, March 30th. Morgan Stanley cut their price objective on Fusion Pharmaceuticals from $19.00 to $10.00 and set an “overweight” rating for the company in a research report on Friday, January 27th. Finally, Brookline Capital Management restated a “buy” rating on shares of Fusion Pharmaceuticals in a research report on Monday, February 13th.

Fusion Pharmaceuticals Stock Performance

NASDAQ FUSN opened at $4.26 on Wednesday. The company has a quick ratio of 12.73, a current ratio of 12.73 and a debt-to-equity ratio of 0.17. Fusion Pharmaceuticals has a twelve month low of $1.98 and a twelve month high of $5.22. The business has a 50-day moving average price of $4.05 and a 200-day moving average price of $3.56. The firm has a market cap of $272.00 million, a price-to-earnings ratio of -2.14 and a beta of -1.14.

Fusion Pharmaceuticals (NASDAQ:FUSN – Get Rating) last posted its quarterly earnings results on Thursday, March 16th. The company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.02. Fusion Pharmaceuticals had a negative return on equity of 49.39% and a negative net margin of 10,176.33%. The business had revenue of $0.14 million during the quarter, compared to the consensus estimate of $0.12 million. As a group, equities research analysts predict that Fusion Pharmaceuticals will post -1.77 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Millennium Management LLC purchased a new position in Fusion Pharmaceuticals in the second quarter worth about $29,000. Virtu Financial LLC purchased a new position in Fusion Pharmaceuticals during the first quarter worth $49,000. Schonfeld Strategic Advisors LLC purchased a new position in Fusion Pharmaceuticals during the first quarter worth $49,000. Prudential Financial Inc. purchased a new position in Fusion Pharmaceuticals during the third quarter worth $44,000. Finally, Renaissance Technologies LLC purchased a new position in Fusion Pharmaceuticals during the third quarter worth $51,000. Hedge funds and other institutional investors own 59.39% of the company’s stock.

Fusion Pharmaceuticals Company Profile

(Get Rating)

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors.